ARS Pharmaceuticals, Inc.(SPRY)Stock Analysis

SPRY Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ARS Pharmaceuticals, Inc. (SPRY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SPRY at 29.7/100 on a 32-signal composite quality model, placing it at rank #2,389 of 2,879 stocks — the bottom half of the AI-ranked universe. SPRY scores in the top quartile across revenue growth (99.1). Areas of concern include balance sheet strength (2.5) and free cash flow (4.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ARS Pharmaceuticals, Inc. reports quarterly revenue of $22.7M, net income of $-60.6M, free cash flow of $-44.9M. Top institutional holders of SPRY by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS, Rubric Capital Management, based on the most recent SEC filings. SPRY trades on the Nasdaq exchange and files with the SEC under CIK 1671858. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SPRY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ARS Pharmaceuticals, Inc. directly from SEC EDGAR.